Literature DB >> 12082089

The cleavage/polyadenylation activity triggered by a U-rich motif sequence is differently required depending on the poly(A) site location at either the first or last 3'-terminal exon of the 2'-5' oligo(A) synthetase gene.

Youssef Aissouni1, Christophe Perez, Boris Calmels, Philippe D Benech.   

Abstract

Production of the two mRNAs encoding distinct forms of 2'-5'-oligoadenylate synthetase depends on processing that involves the recognition of alternative poly(A) sites and an internal 5'-splice site located within the first 3'-terminal exon. The resulting 1.6- and 1.8-kb mRNAs are expressed in fibroblast cell lines, whereas lymphoblastoid B cells, such as Daudi, produce only the 1.8-kb mRNA. In the present study, we have shown that the 3'-end processing at the last 3'-terminal exon occurs independently of the core poly(A) site sequence or the presence of regulatory elements. In contrast, in Daudi cells, the recognition of the poly(A) site at the first 3'-terminal exon is impaired because of an unfavorable sequence context. The 3'-end processing at this particular location requires a strong stabilization of the cleavage/polyadenylation factors, which can be achieved by the insertion of a 25-nucleotide long U-rich motif identified upstream of the last poly(A) site. Consequently, we speculate that in cells expressing the 1.6-kb mRNA, such as fibroblasts, direct or indirect participation of a specific mechanism or cell type-specific factors are required for an efficient polyadenylation at the first 3'-terminal exon.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12082089     DOI: 10.1074/jbc.M200540200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Analysis of a noncanonical poly(A) site reveals a tripartite mechanism for vertebrate poly(A) site recognition.

Authors:  Krishnan Venkataraman; Kirk M Brown; Gregory M Gilmartin
Journal:  Genes Dev       Date:  2005-06-01       Impact factor: 11.361

Review 2.  A systematic analysis of disease-associated variants in the 3' regulatory regions of human protein-coding genes II: the importance of mRNA secondary structure in assessing the functionality of 3' UTR variants.

Authors:  Jian-Min Chen; Claude Férec; David N Cooper
Journal:  Hum Genet       Date:  2006-06-29       Impact factor: 4.132

3.  Novel upstream and downstream sequence elements contribute to polyadenylation efficiency.

Authors:  Sarah K Darmon; Carol S Lutz
Journal:  RNA Biol       Date:  2012-10-01       Impact factor: 4.652

4.  Human Fip1 is a subunit of CPSF that binds to U-rich RNA elements and stimulates poly(A) polymerase.

Authors:  Isabelle Kaufmann; Georges Martin; Arno Friedlein; Hanno Langen; Walter Keller
Journal:  EMBO J       Date:  2004-01-29       Impact factor: 11.598

5.  Association of SARS susceptibility with single nucleic acid polymorphisms of OAS1 and MxA genes: a case-control study.

Authors:  Jing He; Dan Feng; Sake J de Vlas; Hongwei Wang; Arnaud Fontanet; Panhe Zhang; Sabine Plancoulaine; Fang Tang; Lin Zhan; Hong Yang; Tianbao Wang; Jan H Richardus; J Dik F Habbema; Wuchun Cao
Journal:  BMC Infect Dis       Date:  2006-07-06       Impact factor: 3.090

6.  Sequence determinants in human polyadenylation site selection.

Authors:  Matthieu Legendre; Daniel Gautheret
Journal:  BMC Genomics       Date:  2003-02-25       Impact factor: 3.969

7.  The relationship between the prothrombin upstream sequence element and the G20210A polymorphism: the influence of a competitive environment for mRNA 3'-end formation.

Authors:  Mythily Sachchithananthan; Stan J Stasinopoulos; Jeffrey Wilusz; Robert L Medcalf
Journal:  Nucleic Acids Res       Date:  2005-02-17       Impact factor: 16.971

8.  Useful Bicistronic Reporter System for Studying Poly(A) Site-Defining cis Elements and Regulation of Alternative Polyadenylation.

Authors:  Zhongyuan Deng; Shen Zhang; Shaohua Gu; Xinzhi Ni; Wenxian Zeng; Xianchun Li
Journal:  Int J Mol Sci       Date:  2018-01-17       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.